Date | Price Target | Rating | Analyst |
---|---|---|---|
8/11/2023 | $4.00 | Overweight → Equal Weight | Wells Fargo |
3/16/2023 | Outperform → Mkt Perform | William Blair | |
12/8/2021 | $19.00 | Overweight | Wells Fargo |
11/16/2021 | $12.00 → $20.00 | Buy | HC Wainwright & Co. |
7/20/2021 | $14.00 | Buy | JonesTrading |
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Kezar Life Sciences (NASDAQ:KZR) with a Buy and lowers the price target from $20 to $7.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) with a Buy and maintains $20 price target.
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.33) by 9.09 percent. This is a 3.23 percent increase over losses of $(0.31) per share from the same period last year.
SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)
SC 13G/A - Kezar Life Sciences, Inc. (0001645666) (Subject)
SC 13G - Kezar Life Sciences, Inc. (0001645666) (Subject)
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference on Wednesday, September, 11, 2024 at 12:00 pm ET in New York, NY. A webcast of the presentation will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days. About Kezar Life Sciences Kezar Life Sciences
Enrollment completed in PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis; revising guidance of topline data to first half 2025 PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis currently enrolling; reiterating guidance of topline data in mid-2026 Enrollment stopped in the KZR-261 Phase 1 study in refractory solid tumors; focusing resources on zetomipzomib development programs Cash, cash equivalents and marketable securities totaled $164 million as of June 30, 2024 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet ne
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 72,000 shares of its common stock with an exercise price of $0.55 per share, which is equal to the closing price of Kezar's common stock on July 8, 2024, the grant date of the award. The stock option was granted as an inducement award material to the individual entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option
10-Q - Kezar Life Sciences, Inc. (0001645666) (Filer)
8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)
8-K - Kezar Life Sciences, Inc. (0001645666) (Filer)
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will pull forward its virtual Research and Development (R&D) Day to Wednesday, March 15, 2023 at 4:30 pm ET/1:30 pm PT. "The goal of Kezar's R&D Day is to set expectations for 2023, provide updates on our two clinical assets, and highlight the productivity from our Discovery team. We are progressing more quickly than planned with initiating PALIZADE, our next study of zetomipzomib for the treatment of lupus nephritis, and look forward to sharing the details," said John Fowler, Kezar's
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a virtual Research and Development (R&D) Day on Wednesday, March 22, 2023 at 4:30 pm ET/1:30 pm PT. Kezar's R&D Day will provide an extensive overview of the Company's pipeline, reviewing next steps on zetomipzomib, including the trial design for the Phase 2b portion of the lupus nephritis development program, as well as on its Protein Secretion Inhibition platform. The event will also highlight the recently announced autoimmune hepatitis (AIH) PORTOLA study, including a presentation
11 of 17 patients (64.7%) achieved an overall renal response of 50% or greater reduction in urine protein to creatinine ratio (UPCR) at 6 months 6 of 17 patients (35.2%) achieved a complete renal response, including a UPCR of 0.5 or less at 6 months Zetomipzomib continues to demonstrate a favorable safety and tolerability profile for administration over the 6-month treatment period Improvement seen in exploratory measures of extra-renal disease activity associated with systemic lupus erythematosus (SLE) in patients who completed treatment Company-hosted conference call and webcast to be held today at 4:30 p.m. ET Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage bi
4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)
4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)
4 - Kezar Life Sciences, Inc. (0001645666) (Issuer)
Strategic realignment to focus capital resources on clinical programs and reduce workforce by approximately 41% Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026 Co-Founder and Board Director, Christopher Kirk, PhD, appointed as Chief Executive Officer Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment
Announced positive topline results from the MISSION Phase 2 Trial evaluating zetomipzomib for the treatment of patients with lupus nephritis Appointed Nick Mordwinkin, Pharm.D., Ph.D. as Chief Business Officer Cash, cash equivalents and marketable securities totaled $306.8 million as of June 30, 2022 Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the second quarter ended June 30, 2022 and provided a business update. "The second quarter was tremendously productive for Kezar, during which we achieved key clinical milestone
Kezar Life Sciences, Inc., (NASDAQ:KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company's Chief Business Officer, the Compensation Committee of the company's Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar's common stock on August 1, 2022. In addition, the Compensation Committee of the company's Board of Directors granted
Wells Fargo downgraded Kezar Life Sciences from Overweight to Equal Weight and set a new price target of $4.00
William Blair downgraded Kezar Life Sciences from Outperform to Mkt Perform
Wells Fargo initiated coverage of Kezar Life Sciences with a rating of Overweight and set a new price target of $19.00